Sector News

Novartis to acquire AveXis for $8.7 billion in cash

April 9, 2018
Life sciences

Novartis AG said Monday that it has entered into an agreement to acquire clinical-stage gene therapy group AveXis Inc. for $8.7 billion in cash, or $218 per share.

Novartis, a Swiss-based pharmaceutical group, said the deal has been unanimously approved by the boards of both companies.

In acquiring AveXis, Novartis said it hopes to expand its role as a leader in gene therapy and neuroscience. Assuming completion by the middle of this year, the Swiss group said the deal would be slightly negative to its core operating income in 2018 and 2019, mainly due to research and development investments. But by 2020, Novartis expects the acquisition to “strongly contribute” to core operating income and earnings per share owing to an expected boost in sales.

By Barbara Kollmeyer

Source: MarketWatch

comments closed

Related News

March 25, 2023

UK regulator makes biggest changes in 20 years to speed up trials, attract global studies

Life sciences

The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.

March 25, 2023

Novo partners with Dewpoint to mine an emerging field for new drugs

Life sciences

Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.

March 25, 2023

Sanofi’s Dupixent receives EC approval for atopic dermatitis

Life sciences

Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.

How can we help you?

We're easy to reach